Matthew Weinberg Writes for International Clinical Trials (ICT) Magazine
August 16, 2013
In this article CEO Matthew Weinberg discusses the downsides to self-auditing good clinical practice and the need smaller, more proactive audits, on the other hand, can provide a more intelligent analysis.
TAGS:
Contact Us
Related Articles
April 23, 2012
CEO Matthew Weinberg Presents at FDA Clinical Trials Hearing
April 23 - The Weinberg Group CEO, Matthew Weinberg, presented today at FDA’s hearing titled “Modernizing the Regulation of Clinical Trials and Approaches to Good Clinical Practice.” Mr. Weinberg...
Drug Companies Face Stricter Clinical Trial Regulation Worldwide
For more information on The Weinberg Group’s independent clinical auditing services, please contact Jeff Antos at jeff.antos@weinberggroup.com or 202.280.0815.
The Weinberg Group to Sponsor and Participate in Linking Leaders Roundtable Series
Linking Leaders’ Clinical Quality roundtable series provides pharmaceutical and biotech executives a forum to share insights and experiences, benchmark progress, and collaborate on solutions with...